GHOST TREE CAPITAL LLC
Q4 2021 Form 13-F

NEW YORK, NEW YORK
CIK 0001595851 · CRD 167435 · SEC-registered investment adviser
$279.0M Reported Value Total

GHOST TREE CAPITAL, LLC reports 9 total accounts under management (AUM). There are 9 discretionary accounts valued at $576,414,823, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Private funds (Form ADV)
3 funds · $194.6M gross asset value
Hedge Fund: $194.6M
Source: Form ADV filed 2025-01-17
Reported value
$279.0M
Quarter over quarter
+2.0%
Holdings
43
Top-10 concentration
47.4%

Key People

Form ADV owners & control persons
David Young-Jae Kim
MANAGING PARTNER; OWNER

Filing Navigation

13F Metrics

Loading 13F Metrics

Q4 2021 13F record

Q4 2021 13F filing summary

Q4 2021 Form 13F portfolio summary
Period of report December 31, 2021
Filed February 16, 2022
Form 13F-HR
Reported value $279.0M
Positions 43
Change in reported value -18.4%
New positions 9
Exited positions 21
Position turnover 46.9%
Top-10 concentration 47.4%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2024 13F
Filed Nov 14, 2024
51 $331.0M
Q2 2024 13F
Filed Aug 14, 2024
59 $319.3M
Q1 2024 13F
Filed May 15, 2024
65 $361.3M
Q4 2023 13F
Filed Feb 14, 2024
44 $305.9M
Q3 2023 13F
Filed Nov 14, 2023
58 $304.1M
Q2 2023 13F
Filed Aug 14, 2023
55 $302.9M
Q1 2023 13F
Filed May 15, 2023
52 $338.3M
Q4 2022 13F
Filed Feb 14, 2023
35 $234.2M
Q3 2022 13F
Filed Nov 14, 2022
35 $356.3M
Q2 2022 13F
Filed Aug 15, 2022
29 $192.0M
Q1 2022 13F
Filed May 16, 2022
39 $460.8M
Q4 2021 13F
Filed Feb 16, 2022
43 $279.0M
Q3 2021 13F
Filed Nov 15, 2021
55 $342.0M
Q2 2021 13F
Filed Aug 11, 2021
49 $363.8M
Q1 2021 13F
Filed May 14, 2021
46 $425.5M
Q4 2020 13F
Filed Feb 16, 2021
40 $448.8M
Q3 2020 13F
Filed Nov 16, 2020
45 $346.0M
Q2 2020 13F
Filed Aug 14, 2020
39 $379.0M
Q1 2020 13F
Filed May 15, 2020
42 $377.0M
Q4 2019 13F
Filed Feb 14, 2020
45 $525.1M

24 earlier quarters on file — choose one from the quarter menu above.

Top 20 holdings · Q4 2021

Largest Q4 2021 13F positions by reported value
# Holding Reported value % of portfolio
1 ASND ASCENDIS PHARMA A/S $25.6M 9.16%
2 APLS APELLIS PHARMACEUTICALS INC $15.4M 5.51%
3 COGT COGENT BIOSCIENCES INC $14.6M 5.23%
4 CLDX CELLDEX THERAPEUTICS INC NEW $13.5M 4.85%
5 RAPT RAPT THERAPEUTICS INC $12.9M 4.61%
6 MRUS MERUS N V $11.1M 3.99%
7 ISEE IVERIC BIO INC $10.5M 3.74%
8 VRDN VIRIDIAN THERAPEUTICS INC $9.9M 3.54%
9 IOVA C IOVANCE BIOTHERAPEUTICS INC $9.5M 3.42%
10 RCKT ROCKET PHARMACEUTICALS INC $9.3M 3.32%
11 ARVN ARVINAS INC $9.0M 3.24%
12 SRPT SAREPTA THERAPEUTICS INC $9.0M 3.23%
13 BLU P BELLUS HEALTH INC NEW $7.2M 2.57%
14 ZNTL ZENTALIS PHARMACEUTICALS INC $6.7M 2.41%
15 SNDX SYNDAX PHARMACEUTICALS INC $6.6M 2.35%
16 PCVX VAXCYTE INC $5.9M 2.13%
17 FOLD AMICUS THERAPEUTICS INC $5.8M 2.07%
18 SRRA SIERRA ONCOLOGY INC $5.4M 1.95%
19 ALNY ALNYLAM PHARMACEUTICALS INC $5.1M 1.82%
20 VRNA VERONA PHARMA PLC $5.0M 1.81%

Values as reported on the Q4 2021 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings